Table 1. Controlled clinical trial selected to review Author/year Intervention Main Outcome Brownley et al., 2013 Receive placebo or 600 and 1000µg/day of CrPic for 6 months ↓fasting plasma glucose ↓binge eating ↓weight HbA1c normalized in 86% of patients under CrPic treatment Masharin et al., 2012 Received 500μg 2x/ day for 16 weeks ↑ serum chromium levels and urinary ↔ insulin sensitivity, body composition, muscle biopsies, PCR analyses, BMI, truncal fat or lipid levels Ali et al.,2011 Offered 2 dosages (500 or 1000 µg/day) for 6 months ↔ glucose and insulin levels, insulin resistance Krikorian et al., 2010 Received 1000 µg/day of CrPic for 12 weeks ↑ cognitive control and cerebral function ↔ depressive symptoms ↑ brain activation Cefalu et al., 2010 Offered 1000µg/day CrPic for 24 weeks ↔body fat and composition measures of “responders” and “nonresponders” ↓myocellular and intrahepatic lipid in “responders” and “nonresponders” Iqbal et al., 2009 Offered 1000µg/day CrPic for 16 weeks ↑acute insulin response to glucose ↔ glucose metabolism, body weight, serum lipids, inflammation and oxidative stress Wang et al., 2007 Received 1000 µg/day of CrPic for 6 months ↑ response to chromium treatment in insulin resistant patients Vrotvec et al., 2005 Received 1000µg CrPic for 3 months ↓ QTc interval of diabetic patients BED: binge eating disorder; BMI: body mass index; CrPic: chromium picolinate; DM: diabetes mellitus; HbA1C: glycated hemoglobin; PCR: protein C reactive. Bruna Marmett et al. Effects of Chromium Picolinate Supplementation on Control of Metabolic Variables: A Systematic Review. Journal of Food and Nutrition Research, 2016, Vol. 4, No. 10, 633-639. doi:10.12691/jfnr-4-10-1 © The Author(s) 2015. Published by Science and Education Publishing.